EurekaMag.com logo
+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The excretion of 5-hydroxyindoleacetic acid in mental patients



The excretion of 5-hydroxyindoleacetic acid in mental patients



Progress in Brain Research 16: 164-168



Reserpine, 2 mg twice daily, was administered to 11 schizophrenic patients and to 6 high-grade mentally defective patients. The excretion of 5-hydroxyindoleacetic acid (5-HIAA) was increased on the first day of medication in both groups of patients. The excretion of the serotonin metabolite after the first day of medication and after its cessation was reduced to premedication levels or less. When these patients were given another course of reserpine at a later date, the excretory pattern of 5-HIAA was essentially the same as during the first course. The most consistent feature of the experiments was the marked rise in the excretion of the serotonin metabolite on the first day of reserpine medication.

(PDF emailed within 1 workday: $29.90)

Accession: 025786683

Download citation: RISBibTeXText

PMID: 5318945



Related references

Study of excretion of 5-hydroxyindoleacetic acid in mental patients. A.M.A. Archives of Neurology and Psychiatry 81(3): 292-298, 1959

Excretion patterns of tryptamine, indoleacetic acid, and 5-hydroxyindoleacetic acid, and their correlation with mental changes in schizophrenic patients under medication with alpha-methyldopa. Psychopharmacologia 15(1): 48-59, 1969

Studies on the 24 hour urinary excretion of 5-hydroxyindoleacetic acid in patients with stomach or duodenal ulcer before, during and after treatment with Spasmophen in relation to the "basal HC1 excretion" and the clinical condition of patients. Polskie Archiwum Medycyny Wewnetrznej 40(6): 683-689, 1968

Excretion of 3-methoxy-4-hydroxymandellc acid and 5-hydroxyindoleacetic acid in depressed patients treated with imipramine. J Psychiat Res 5(3): 213-220, 1967

5-Hydroxyindoleacetic acid excretion in patients with the glossalgia syndrome. Stomatologiia 61(1): 34-35, 1982

Excretion of 5-hydroxyindoleacetic acid in patients irradiated therapeutically. International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine 24(5): 443-448, 1973

Excretion of 3-methoxy-4-hydroxy-amygdalic acid and 5-hydroxyindoleacetic acid in the urine of patients with depressive states. Przeglad Lekarski 24(3): 367-370, 1968

Excretion of 5-hydroxyindoleacetic acid and vanilmandelic acid in patients with glaucoma. Ceskoslovenska Oftalmologie 23(3): 177-186, 1967

24-hour excretion of 5-hydroxyindoleacetic acid and 3-methoxy-4-hydroxymandelic acid in patients with partial gastrectomy for peptic ulcer. Polski Tygodnik Lekarski 28(5): 168-171, 1973

The urinary excretion of 5-hydroxyindoleacetic acid in patients with menopausal flushing. Jour Clin Pathol 13(6): 518, 1960

Urinary excretion of 5-hydroxyindoleacetic acid by patients with chronic schizophrenia. Psychiatria Polska 1(1): 45-52, 1967

Urinary excretion of 5-hydroxyindoleacetic acid in patients treated for Hodgkin's disease. Wiadomosci Lekarskie 29(20): 1795-1797, 1976

Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors. Clinical Chemistry 50(9): 1634-1639, 2004

Investigations on urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA) in patients after cerebral stroke. Polish Medical Journal 7(4): 974-979, 1968

Blood serotonin (5-HT) level and 24 hrs urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA) in patients with active liver cirrhosis and in patients with hepatic encephalopathy. Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 46: 75-80, 1991